Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised Phase II Study of Pembrolizumab With or Without Bevacizumab in Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma

NCT03813394 is registered in ClinicalTrials.gov with National University Hospital, Singapore as lead sponsor.

NCT NCT03813394
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03813394 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised Phase II Study of Pembrolizumab With or Without Bevacizumab in Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma
Lead sponsor
National University Hospital, Singapore
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
May 1, 2019
Completion date
June 1, 2025
Enrollment
48 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

locally recurrent cancer, metastatic nasopharyngeal cancer